Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers

Completed

Conditions studied: Sickle Cell Disease

In brief

This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with patients who had initiated crizanlizumab between 2019 and 2022.

Key facts

Study ID

NCT06662825

Run by

Novartis

People needed

376

Starts

2022-12-13

Expected to finish

2023-11-01

Last updated by the study team

2024-10-29

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any patient with a diagnosis of SCD based on high performance liquid chromatography (HPLC) or hemoglobin electrophoresis at treating institution.
• Treatment order for crizanlizumab; Index date was defined as the date for the first crizanlizumab treatment.
• At least 12 months of available electronic medical record (EMR) data pre-index date (baseline).
• Patients must have received at least one dose of crizanlizumab.
• For inclusion in pre/post analysis of effectiveness, patients must have received crizanlizumab for at least 12 months.
• Exclusion criteria None identified.

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.